![]() | |
Names | |
---|---|
Preferred IUPAC name N-(3-{(4aR,5S,8R,8aS)-1-[(4-Fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2,4a,5,6,7,8,8a-octahydro-5,8-methanoquinolin-3-yl}-1,1-dioxo-1,4-dihydro-1λ6,2,4-benzothiadiazin-7-yl)methanesulfonamide [1] | |
Other names ANA-598; ANA598 | |
Identifiers | |
3D model (JSmol) | |
ChEMBL | |
ChemSpider | |
KEGG | |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
| |
| |
Properties | |
C25H25FN4O6S2 | |
Molar mass | 560.62 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Setrobuvir (also known as ANA-598) was an experimental drug candidate for the treatment of hepatitis C that was discovered at Anadys Pharmaceuticals, which was acquired by Roche in 2011; Roche terminated development in July 2015. [2] [3] It was in Phase IIb clinical trials, used in combination with interferon and ribavirin, targeting hepatitis C patients with genotype 1. [3]
Setrobuvir works by inhibiting the hepatitis C enzyme NS5B, an RNA polymerase. [4]